Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis

Completed

Conditions studied: Idiopathic Pulmonary Fibrosis (IPF)

In brief

Drug discovery can take many years especially since most studies to measure effectiveness depend on clinical outcomes like pulmonary function tests and hospitalizations. This is an observational study designed to collect information, blood, and bronchoalveolar lavage fluid in people who have IPF and those who do not. The people who have IPF will be followed for 12 months to collect more biological samples and record clinically relevant information. The goal of this study is to identify new molecular markers that are measurable and reliable in people who have IPF. It is hoped that these markers can be used in future drug studies to significantly speed up the process of finding drugs that help.

Key facts

Study ID

NCT01718990

Run by

University of California, San Francisco

People needed

110

Starts

2012-10-01

Expected to finish

2018-12-31

Last updated by the study team

2020-07-31

Who can join

Age: 35 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age 35 to 80 years
• a diagnosis of IPF by consensus criteria

You may not qualify if…

• any condition that makes the patient at unacceptable risk for bronchoscopy
• the presence of significant co-existing emphysema on HRCT
• active cigarette smoking (defined as smoking within the last 6 months)
• the presence of a significant co-morbidity felt to limit life expectancy to less than 12 months.
• active listing for lung transplantation
• inability to provide informed consent

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.